Skip to main content
Livermore
Livermore
ZHEN

Foresite Capital Management V, LLC

SEC CIK
0001792206
Latest filing
Aug 14, 2026

The latest 13F from Foresite Capital Management V, LLC covers Q2 2026 (filed Aug 14, 2026): 9 long positions worth $362.2M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Alumis Inc. (ALMS) at 45.8%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
1
Est. +$13.3M
Added
2
Est. +$21.6M
Reduced
1
Est. −$9.72K
Sold out
1
Est. −$773.3K

Top 5 holdings

Share of this quarter's portfolio value

  1. ALMSAlumis Inc.
    45.8%$165.9MHistory
  2. CGONCG Oncology, Inc.
    21.2%$76.7MHistory
  3. IRONDisc Medicine, Inc.
    7.6%$27.4MHistory
  4. HIMSHims & Hers Health, Inc.
    7.1%$25.6MHistory
  5. PHVSPharvaris N.V.
    6.3%$23.0MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. PHVSPharvaris N.V.
    +$16.3MAddedHistory
  2. ODTXOdyssey Therapeutics, Inc.
    +$13.3MNewHistory
  3. CGONCG Oncology, Inc.
    +$5.33MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. PHVSPharvaris N.V.
    +4.32 pp2.0% → 6.3%History
  2. ODTXOdyssey Therapeutics, Inc.
    +3.68 pp0.0% → 3.7%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. MAZEMaze Therapeutics, Inc.
    −$773.3KSold outHistory
  2. LYELLyell Immunopharma, Inc.
    −$9.72KReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. LYELLyell Immunopharma, Inc.
    −1.68 pp3.5% → 1.8%History
  2. MAZEMaze Therapeutics, Inc.
    −0.29 pp0.3% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$362.2M
+$91.2M (+33.7%) vs. prior quarter
Positions
9
0 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
0.2%
Q2 2026, one quarter
Average holding period
9.3 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $407.0M (Q4 2021)

Q1 2021: $340.2MQ2 2021: $254.2MQ3 2021: $321.8MQ4 2021: $407.0MQ1 2022: $244.9MQ2 2022: $143.1MQ3 2022: $130.1MQ4 2022: $128.8MQ1 2023: $135.3MQ2 2023: $136.9MQ3 2023: $62.7MQ4 2023: $73.4MQ1 2024: $106.5MQ2 2024: $156.6MQ3 2024: $143.9MQ4 2024: $120.2MQ1 2025: $87.6MQ2 2025: $80.7MQ3 2025: $108.7MQ4 2025: $164.4MQ1 2026: $271.0MQ2 2026: $362.2M
Q1 2021Q2 2026
13F filings of Foresite Capital Management V, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 20269$362.2MALMSCGONIRONvs. Q1 2026SEC
Q1 2026May 15, 20269$271.0MALMSCGONIRONvs. Q4 2025SEC
Q4 2025Feb 17, 20267$164.4MALMSCGONIRONvs. Q3 2025SEC
Q3 2025Nov 14, 20256$108.7MCGONALMSIRONvs. Q2 2025SEC
Q2 2025Aug 12, 20256$80.7MCGONALMSIRONvs. Q1 2025SEC
Q1 2025May 15, 20256$87.6MALMSCGONIRONvs. Q4 2024SEC
Q4 2024Feb 14, 20256$120.2MALMSHIMSCGONvs. Q3 2024SEC
Q3 2024Nov 14, 20245$143.9MALMSHIMSCGONvs. Q2 2024SEC
Q2 2024Aug 13, 20245$156.6MALMSHIMSCGONvs. Q1 2024SEC
Q1 2024May 15, 20245$106.5MHIMSCGONIRONvs. Q4 2023SEC
Q4 2023Feb 13, 20245$73.4MHIMSTHRXIRONvs. Q3 2023SEC
Q3 2023Nov 13, 20237$62.7MHIMSIRONTHRXvs. Q2 2023SEC
Q2 2023Aug 11, 202310$136.9MHIMSTHRXPRDSvs. Q1 2023SEC
Q1 2023May 12, 202311$135.3MHIMSTHRXPRDSvs. Q4 2022SEC
Q4 2022Feb 13, 202311$128.8MHIMSCMPXACRSvs. Q3 2022SEC
Q3 2022Nov 14, 202214$130.1MACRSTHRXHIMSvs. Q2 2022SEC
Q2 2022Aug 12, 202214$143.1MPRDSTHRXACRSvs. Q1 2022SEC
Q1 2022May 13, 202217$244.9MPRDSTHRXSLGCvs. Q4 2021SEC
Q4 2021Feb 11, 202216$407.0MPRDSSLGCTHRXvs. Q3 2021SEC
Q3 2021Nov 12, 202117$321.8MSLGCCGEMIVVDvs. Q2 2021SEC
Q2 2021Aug 16, 202117$254.2MCGEMQSIACRSvs. Q1 2021SEC
Q1 2021May 17, 202120$340.2MCGEMIRONACRS–SEC

13D and 13G filings

Companies where Foresite Capital Management V, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Foresite Capital Management V, LLC does not currently report owning 5% or more of any company.

Latest filings

15 filings on file made by Foresite Capital Management V, LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Foresite Capital Management V, LLC
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
LTGOLatigo Biotherapeutics, Inc.Aug 17, 20267:06 PM ETForesite Capital Fund VI LPand 6 others13D14.50%9.18M sharesNewAug 10, 2026SEC
ALMSAlumis Inc.Aug 17, 20266:09 AM ETForesite Capital Fund VI LPand 6 others13D14.50%9.18M sharesNewAug 10, 2026SEC
LYELLyell Immunopharma, Inc.Aug 14, 20264:03 PM ETForesite Capital Fund IV, L.P.and 6 others13G/A2.70%653.3K shares−4.90 ppfrom 7.60%Below 5%Jun 30, 2026SEC
CGONCG Oncology, Inc.Aug 14, 20264:01 PM ETForesite Capital Fund V, L.P.and 6 others13G/A4.90%4.31M shares–Below 5%Jun 30, 2026SEC
ALMSAlumis Inc.Apr 3, 20263:51 PM ETForesite Capital Fund VI LPand 11 others13D/A12.70%15.7M shares−1.40 ppfrom 14.10%Apr 1, 2026SEC
EIKNEikon Therapeutics, Inc.Feb 11, 20264:08 PM ETForesite Capital Fund IV, L.P.and 8 others13G7.70%4.15M sharesNewFeb 4, 2026SEC
ALMSAlumis Inc.Jan 12, 20269:59 PM ETForesite Capital Fund VI LPand 11 others13D/A14.10%16.2M shares−1.80 ppfrom 15.90%Jan 8, 2026SEC
LYELLyell Immunopharma, Inc.Nov 14, 20254:05 PM ETForesite Capital Fund IV, L.P.and 6 others13G/A7.60%1.45M shares−1.60 ppfrom 9.20%Sep 30, 2025SEC
MAZEMaze Therapeutics, Inc.Nov 14, 20254:04 PM ETForesite Capital Fund IV, L.P.and 4 others13G/A1.40%608.9K shares−4.20 ppfrom 5.60%Below 5%Sep 30, 2025SEC
ALMSAlumis Inc.Jun 10, 20254:37 PM ETForesite Capital Fund VI LPand 11 others13D/A15.90%15.2M shares−16.30 ppfrom 32.20%May 21, 2025SEC
LYELLyell Immunopharma, Inc.May 15, 20254:04 PM ETForesite Capital Fund IV, L.P.and 6 others13G/A9.20%27.2M shares+2.50 ppfrom 6.70%Mar 31, 2025SEC
ALMSAlumis Inc.May 7, 20253:33 PM ETForesite Capital Fund VI LPand 11 others13D/A32.20%15.2M shares–Aug 13, 2024SEC
LYELLyell Immunopharma, Inc.Feb 14, 20252:20 PM ETForesite Capital Fund IV, L.P.and 6 others13G/A6.70%19.5M shares–Dec 31, 2024SEC
MAZEMaze Therapeutics, Inc.Feb 7, 20254:01 PM ETForesite Capital Fund IV, L.P.and 4 others13G5.60%2.46M shares0.00 ppfrom 5.60%Jan 31, 2025SEC
MAZEMaze Therapeutics, Inc.Feb 7, 20254:01 PM ETForesite Capital Fund IV, L.P.and 4 others13G5.60%2.46M sharesNewJan 31, 2025SEC